Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist

Brian G Drew; Anna C Calkin

Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist

Curr Opin Investig Drugs. 2007 Apr;8(4):324-30.

Authors

Brian G Drew¹, Anna C Calkin

Affiliation

¹ Baker Heart Research Institute, Juvenile Diabetes Research Foundation Centre for Diabetes Complications, PO Box 6492, St Kilda Road Central, Melbourne 8008, Australia.

PMID: 17458183

Abstract

Kozva Co Ltd, under license from Roche Holding AG, is developing K-111, an orally available peroxisome proliferator-activated receptor a ligand and insulin-potentiating agent, for the potential treatment of type 2 diabetes. Phase II clinical trials of K-111 are underway.

Publication types

Review

MeSH terms

Animals
Clinical Trials, Phase II as Topic
Diabetes Mellitus, Type 2 / drug therapy
Drug Evaluation / methods*
Drug Evaluation, Preclinical / methods
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Insulin / pharmacology
Insulin / therapeutic use*
Lauric Acids / pharmacology
Lauric Acids / therapeutic use*
PPAR alpha / agonists*

Substances

2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid
Hypoglycemic Agents
Insulin
Lauric Acids
PPAR alpha